Pfizer & Eli Lilly Report Results of Tanezumab in Long-Term P-III Study for Osteoarthritis

Shots:

• The P-III A4091058 study involves assessing of Tanezumab (2.5 & 5mg, q8w) vs NSAIDS (naproxen 500 mg/celecoxib 100 mg/diclofenac extended release 75 mg, q2d) in 3,021 patients with moderate-to-severe OA in ratio 1:1:1 for 56wks. across globe + 24-week safety follow-up study
• The P-III A4091058 results: composite 1EPs for safety (3.8% & 7.1% vs 1.5%); incidence of RPOA (3.2% & 6.3% vs 1.2%); joint replacement (5.3% & 8.0% vs 2.6%); subchondral fracture (6&7 vs 4) no pathological fracture observed; one case of osteonecrosis with tanezumab 5 mg
• Tanezumab is a mAb that selectively targets nerve growth factor (NGF) act against pain without producing addiction and has received FDA’s FT designation for OA and chronic low back pain

Click here to read full press release/ article | Ref: Pfizer | Image: The Telegraph